crenolanib
Small moleculeexperimental
Crenolanib besylate is an investigational inhibitor being developed by AROG Pharmaceuticals, LLC. As of 2014, the compound was being evaluated for safety and efficacy in clinical trials for various types of cancer, including acute myeloid leukemia (AML), gastrointestinal stromal tumor (GIST), and glioma. — Wikipedia
Clinical trial activity
14 trials · 12 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
10
Phase 3
4
Phase 4
0
Earliest trial started Dec 1, 2005 (NCT00949624)
Timeline
Indications
Mechanism of action
FLT3 inhibitor
Platelet-derived growth factor receptor inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CC1(COc2ccc3c(c2)ncn3-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1- Mol. weight
- 443.55 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaCrenolanib ↗
- ChEMBLCHEMBL2105728 ↗
Also known as
- aro-002
- aro-002
- cp-868596
- cp-868596
- cp-868,596
- cp-868,596
- cp-868,596
- crenolanib
- crenolanib
- crenolanib
- crenolanib
- crenolanib
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03258931 | Phase 3 | Aug 15, 2018 | Arog Pharmaceuticals, Inc. |
| NCT03250338 | Phase 3 | Jun 5, 2018 | Arog Pharmaceuticals, Inc., State University of New York, Buffalo |
| NCT03324243 | Phase 2 | Jan 31, 2018 | Arog Pharmaceuticals, Inc. |
| NCT03193918 | Phase 1 | Apr 14, 2017 | Arog Pharmaceuticals, Inc., Cornell University |
| NCT02298166 | Phase 3 | Nov 17, 2016 | University of Ulm |
| NCT02847429 | Phase 3 | Aug 1, 2016 | Arog Pharmaceuticals, Inc., Centre Leon Berard, Temple University |
| NCT02626364 | Phase 2 | Apr 1, 2016 | Arog Pharmaceuticals, Inc., University of Texas at Houston |
| NCT02626338 | Phase 1/Phase 2 (Phase 2) | Feb 1, 2016 | Arog Pharmaceuticals, Inc. |
| NCT02270788 | Phase 1 | Apr 2, 2015 | Arog Pharmaceuticals, Inc., Ohio State University, St. Jude Children's Hospital |
| NCT02283177 | Phase 2 | Jan 1, 2015 | Arog Pharmaceuticals, Inc. |
| NCT01393912 | Phase 1 | Jul 1, 2011 | Arog Pharmaceuticals, Inc., St. Jude Children's Hospital, V Foundation |
| NCT01229644 | Phase 2 | Apr 1, 2011 | Arog Pharmaceuticals, Inc., The University of Texas, Dallas |
| NCT00386555 | Phase 2 | May 1, 2007 | Arog Pharmaceuticals, Inc., Pfizer |
| NCT00949624 | Phase 1 | Dec 1, 2005 | Arog Pharmaceuticals, Inc., Pfizer |
Showing 14 of 14 trials
Page 1 / 1
Organizations
Research & Development (12)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Arog Pharmaceuticals, Inc. | For profit | 13 | 11 | 3 | 2005 |
| Pfizer | For profit | 2 | 0 | 2 | 2005 |
| St. Jude Children's Hospital | Academic/Hospital | 2 | 2 | 1 | 2011 |
| Centre Leon Berard | Academic/Hospital | 1 | 0 | 1 | 2016 |
| Cornell University | Academic/Hospital | 1 | 0 | 1 | 2017 |
| Ohio State University | Academic/Hospital | 1 | 0 | 1 | 2015 |
| State University of New York, Buffalo | Academic/Hospital | 1 | 0 | 1 | 2018 |
| Temple University | Academic/Hospital | 1 | 0 | 1 | 2016 |
| The University of Texas, Dallas | Academic/Hospital | 1 | 0 | 1 | 2011 |
| University of Texas at Houston | Academic/Hospital | 1 | 0 | 1 | 2016 |
| University of Ulm | Academic/Hospital | 1 | 1 | 1 | 2016 |
| V Foundation | Academic/Hospital | 1 | 0 | 1 | 2011 |
12 organizations
Page 1 / 1